Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Severe Acute Respiratory Syndrome (SARS) Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Overview | 9 | 1 |
| Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Comparative Analysis | 10 | 1 |
| Severe Acute Respiratory Syndrome (SARS) Therapeutics under Development by Companies | 11 | 1 |
| Severe Acute Respiratory Syndrome (SARS) Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Severe Acute Respiratory Syndrome (SARS) Pipeline Products Glance | 13 | 2 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Severe Acute Respiratory Syndrome (SARS) Products under Development by Companies | 15 | 1 |
| Severe Acute Respiratory Syndrome (SARS) Products under Investigation by Universities/Institutes | 16 | 1 |
| Severe Acute Respiratory Syndrome (SARS) Companies Involved in Therapeutics Development | 17 | 8 |
| CEL-SCI Corporation | 17 | 1 |
| GeneCure LLC | 18 | 1 |
| Inovio Pharmaceuticals, Inc. | 19 | 1 |
| Nanotherapeutics, Inc. | 20 | 1 |
| Novavax, Inc. | 21 | 1 |
| Phelix Therapeutics, LLC | 22 | 1 |
| Planet Biotechnology Inc. | 23 | 1 |
| Protein Sciences Corporation | 24 | 1 |
| Severe Acute Respiratory Syndrome (SARS) Therapeutics Assessment | 25 | 9 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Combination Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 1 |
| Assessment by Molecule Type | 32 | 2 |
| Drug Profiles | 34 | 16 |
| CEL-1000 Drug Profile | 34 | 2 |
| D-3252 Drug Profile | 36 | 1 |
| Drugs to Inhibit Cathepsin L for Infectious Diseases Drug Profile | 37 | 1 |
| FDX-000 Drug Profile | 38 | 1 |
| Gene Therapy for Severe Acute Respiratory Syndrome Drug Profile | 39 | 1 |
| INO-4500 Drug Profile | 40 | 2 |
| Middle East respiratory syndrome coronavirus vaccine Drug Profile | 42 | 1 |
| Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine Drug Profile | 43 | 1 |
| ML-188 Drug Profile | 44 | 1 |
| Monoclonal Antibody for SARS Virus Infections Drug Profile | 45 | 1 |
| RBD-219N1 Drug Profile | 46 | 1 |
| SARS (virus like particle) vaccine Drug Profile | 47 | 1 |
| severe acute respiratory syndrome vaccine Drug Profile | 48 | 1 |
| SSYA-10001 Drug Profile | 49 | 1 |
| Severe Acute Respiratory Syndrome (SARS) Dormant Projects | 50 | 3 |
| Severe Acute Respiratory Syndrome (SARS) Discontinued Products | 53 | 1 |
| Severe Acute Respiratory Syndrome (SARS) Product Development Milestones | 54 | 1 |
| Featured News &Press Releases | 54 | 1 |
| Oct 19, 2015: Inovio and Partner Advance MERS Vaccine | 54 | 1 |
| Appendix | 55 | 2 |
| Methodology | 55 | 1 |
| Coverage | 55 | 1 |
| Secondary Research | 55 | 1 |
| Primary Research | 55 | 1 |
| Expert Panel Validation | 55 | 1 |
| Contact Us | 55 | 1 |
| Disclaimer | 56 | 1 |